“The Global Pharmaceutical Wholesale & Distribution market is estimated to be worth $1.3bn in 2023” says new Visiongain report

03 October 2018
Pharma

Visiongain has launched a new pharma report: Top 20 Pharmaceutical Wholesale & Distribution Organizations 2018: Branded Drugs, Generic Drugs, Leading Companies

Growth in the global pharmaceutical wholesale and distribution market has remained steady in recent years. Growth is being held back by government price reductions and generic substitution of expensive branded drugs. However, the global demand for prescription medication is increasing. The ageing population in the developed markets is resulting in increasing prevalence of age-related diseases, which require medical treatment. In the emerging markets, the rapidly expanding middle class and increasing spending on healthcare is creating a high demand for medication. The pharmaceutical wholesale and distribution market is poised for strong growth.

The lead analyst of the report commented "Currently, most emerging pharmaceutical wholesale markets are much more fragmented than their developed counterparts. For example, in the US, the top 3 companies account for more than 95% of the country’s total market. China has seen rapid consolidation in recent years; there, the top 2 companies currently account for more than 45% of the market. The Chinese market will see further rapid consolidation during the forecast period.

During the forecast period there will be significant consolidation in the emerging markets. This will lead to a greater number of national wholesalers, able to serve all regions with greater efficiency and lower costs."

Leading companies featured in the report include Alfresa Holdings, AmerisourceBergen, Anda Inc., Cardinal Health, CR Pharmaceutical, CuraScript Special, Fortissa Limited, H.D. Smith, Mawdsley-Brooks & Co. Ltd., McKesson, MEDIPAL HOLDINGS, Morris & Dickson Co. LLC, North Carolina Mutual Wholesale Drug, Prodigy Health, Shanghai Pharmaceutical Holdings., SINOPHARM, Smith Drug Company, SUZUKEN, The PHOENIX Group, Walgreens Boots Alliance

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focussing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Biological API Manufacturing Services Market Report 2021-2031

Demand in the early years of the forecast period will come from multinational biotech looking to sign deals with Indian companies and take advantage of the cheaper costs of production for the emerging market.

08 January 2021

Read

Visiongain Publishes Anaesthesia & Respiratory Devices Market Report 2020-2030

The growth can be attributed to the rising prevalence of respiratory diseases, growing awareness for respiratory diseases, and innovations in respiratory and anesthesia devices. However, unfavourable reimbursement policies and lack of patient adherence in respiratory diseases are some of the factors restraining the growth of the anesthesia and respiratory devices market.

07 January 2021

Read

Visiongain Publishes Inactivated Vaccines Market Report 2020-2030

Factors such as rise in the prevalence of the infectious and bacterial diseases and active participation of government in vaccine development are driving the growth of this market. While high cost of vaccine development is the key factor emerging as a growth barrier over years in this market.

07 January 2021

Read

Visiongain Publishes Human Microbiome Therapeutics Market Report 2021-2031

The potential of microbiome-based drugs as novel treatments to address the unmet needs for many diseases has contributed intensively to the rapid emergence of many investors in this area. Currently, no regulatory framework exists and no drugs have received FDA approval. However, there are several preclinical and clinical-stage companies working with various approaches to develop microbiome-based therapies.

06 January 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever